𝔖 Bobbio Scriptorium
✦   LIBER   ✦

MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese

✍ Scribed by Jing Dong; Binhui Ren; Zhibin Hu; Jiaping Chen; Lingmin Hu; Juncheng Dai; Guangfu Jin; Lin Xu; Hongbing Shen


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
77 KB
Volume
50
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Murine double minute 2 (MDM2) is a negative regulator of the tumor suppressor gene p53. Single nucleotide polymorphisms in MDM2 and p53 can affect patient's response to chemotherapy as well as overall survival of many cancers. This study aimed to assess the associations between polymorphisms in MDM2 and p53 and survival of non‐small cell lung cancer (NSCLC) patients in Chinese. We selected and genotyped both potentially functional SNPs and tagging SNPs in MDM2 and p53 using Illumina Golden Gate platform in a cohort of 568 NSCLC patients. Associations between genotypes and NSCLC median survival time (MST) were assessed using the Kaplan–Meier method. Cox proportional hazard models were performed with the adjustment for age, stage, smoking, histology, surgical operation, and chemo‐ or radiotherapy status. We found that the MDM2 SNP309 (rs2279744) GT/TT genotypes were associated with a significantly worse survival (MST: 23.0 mo for GT/TT vs. 33.0 mo for GG; log‐rank P = 0.028). In the multivariate Cox regression analyses, the MDM2 SNP309GT/TT genotypes were associated with a 1.42‐fold [HR = 1.42, 95% confidence interval (CI), 1.09–1.84] increased risk of death of NSCLC, compared with SNP309GG genotype. MDM2 SNP309 may be used as one of the candidate biomarkers to predict NSCLC survival. © 2011 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Targeting BCL-2 family proteins to overc
✍ Emmanuelle Wesarg; Sandra Hoffarth; Rainer Wiewrodt; Monika Kröll; Stefan Bieste 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 422 KB

## Abstract Cytotoxic chemotherapies are standard of care for patients suffering from advanced non‐small cell lung cancer (NSCLC). However, objective responses are only achieved in 20% of cases and long‐term survival is rarely observed. Clinically applied anticancer drugs exert at least some of the

Host immune gene polymorphisms were asso
✍ Juncheng Dai; Zhibin Hu; Jing Dong; Lin Xu; Shiyang Pan; Yue Jiang; Guangfu Jin; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 313 KB 👁 2 views

## Abstract Laboratory‐based studies showed that host immune genes could influence the prognosis of non‐small‐cell lung cancer (NSCLC). Therefore, genetic polymorphisms in host immune genes may serve as predictors for NSCLC clinical outcome. To test the hypothesis that functional single nucleotide

Reduced survival in patients with stage-
✍ Rafael Rosell; Alex Pifarré; Mariano Monzó; Julio Astudillo; M. Paz López-Cabrer 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 88 KB 👁 2 views

To better understand whether replication-error-type instability (RER 1 ) is a frequent genetic alteration event in surgicalpathologic stage-I non-small-cell lung cancer (NSCLC) and identify whether it constitutes an independent prognostic parameter, we examined 35 surgical-pathologic stage-I-NSCLC p